Relationship between central corneal thickness and progression of visual field loss in patients with open-angle glaucoma

Can J Ophthalmol. 2012 Apr;47(2):155-8. doi: 10.1016/j.jcjo.2012.01.008. Epub 2012 Mar 13.

Abstract

Objective: To determine whether a relationship exists between central corneal thickness (CCT) and visual field (VF) progression in treated patients with open-angle glaucoma and asymmetric corneal thickness.

Design: Retrospective chart review.

Participants: We studied 100 charts of patients with open-angle glaucoma and also bilateral CCT and VF data.

Methods: Charts from 2 glaucoma subspecialty practices were reviewed. The CCT and the rate of progression and event analysis of visual field data were assessed in all subjects. Subanalysis was performed for subjects whose CCT asymmetry was ≥ 16 μm.

Results: The mean CCT was 544 ± 40 μm OD and 541 ± 40 μm OS. The mean CCT difference between fellow eyes was 15 ± 11 μm (range, 1 to 52 μm). There was no significant intrasubject difference in the mean deviation (MD) and the pattern standard deviation (PSD) (p =0.917 and p = 0.704, respectively; paired t test). The more advanced VF MDs and PSDs were found in the thin eyes of 47 and 50 subjects, respectively (p = 0.459 and p = 0.317, respectively; χ(2)). Of the 65 subjects whose visual field indexes were available, 34 had the more rapid visual field index rates of progression in the thin eye (p = 0.400; χ(2)). Of the 27 subjects for whom event analysis was available, 15 had the worse progression category in the thin eye (p = 0.453, χ2). Subgroup analysis of 48 subjects with ≥ 16 μm CCT asymmetry did not find any significant difference in analyses of field progression between fellow eyes.

Conclusions: No relationship was found between CCT and VF loss in treated patients with primary open-angle glaucoma or normal-tension glaucoma with asymmetrical CCT. Specifically, the thin eye did not have the more advanced VF loss or more rapid VF progression.

MeSH terms

  • Aged
  • Antihypertensive Agents / therapeutic use
  • Cornea / pathology*
  • Disease Progression
  • Female
  • Glaucoma, Open-Angle / drug therapy
  • Glaucoma, Open-Angle / physiopathology*
  • Humans
  • Intraocular Pressure / physiology
  • Male
  • Retrospective Studies
  • Tonometry, Ocular
  • Vision Disorders / physiopathology*
  • Visual Fields*

Substances

  • Antihypertensive Agents